Cannabigerol (CBG) is a non-psychoactive cannabinoid and minor constituent of cannabis.[1][2][3][4] It is one of more than 120 identified cannabinoids found in the plant genus Cannabis.[5][6] The compound is the decarboxylated form of cannabigerolic acid (CBGA), the parent molecule from which other cannabinoids are biosynthesized.[2][7] During plant growth, most of the CBG is converted into other cannabinoids, primarily tetrahydrocannabinol (THC) or cannabidiol (CBD), leaving about 1% CBG in finished plant material.[8] Some strains, however, produce larger amounts of CBG and CBGA, while having low quantities of other cannabinoids, like THC and CBD.[9] The pharmacodynamics of CBG are complex.[1][2][3] It is a relatively weak ligand of the cannabinoid receptors, where it acts as a weak partial agonist.[1][2][3] Conversely, it is a much more potent agonist of the α2-adrenergic receptor, antagonist of the serotonin 5-HT1A receptor, and antagonist of the transient receptor potential channel TRPM8.[1][2][3] CBG also has a variety of other actions that may additionally contribute to its effects.[1][2][3] Anti-microbial, anti-inflammatory, and anti-nociceptive effects[15] Neuroprotective properties via mitigation of oxidative stress[15] Potential anti-tumor agent[15] Potential efficacy in treatment of chemotherapy-induced muscle atrophy and weight loss[15]
Related
Related